Ralliant (NYSE: RAL) disclosed its quarterly earnings results on Wednesday, revealing a significant loss. The company reported earnings per share of ($12.10), falling short of analysts’ consensus estimates of $0.67 by $12.77. In response to these unexpected results, Ralliant updated its earnings guidance for the first quarter of 2026 to a range of 0.460-0.520 EPS, while its full-year guidance for 2026 now stands at 2.220-2.420 EPS.
Despite the disappointing earnings report, Ralliant’s stock saw a modest increase. During trading hours on Wednesday, shares climbed by 2.5%, reaching $56.11. A total of 2,847,355 shares changed hands, significantly surpassing the average trading volume of 1,384,394. Over the past year, Ralliant has experienced a low of $40.70 and a high of $57.02. Currently, the company’s market capitalization stands at $6.33 billion, with a price-to-earnings ratio of 44.18. Financial metrics indicate a debt-to-equity ratio of 0.39, a quick ratio of 1.03, and a current ratio of 1.49. Ralliant’s 50-day moving average is $51.78, while its 200-day moving average is $46.76.
Dividend Announcement and Analyst Ratings
In a separate announcement, Ralliant declared a quarterly dividend of $0.05 per share, scheduled for payment on March 23, 2026. Shareholders recorded as of March 9, 2026 will be eligible for the dividend, resulting in an annualized dividend of $0.20 and a yield of 0.4%. The ex-dividend date is also set for March 9, 2026. Currently, Ralliant’s dividend payout ratio is 15.75%.
Analysts have been actively reviewing Ralliant’s performance. In a report dated December 29, 2025, Weiss Ratings reaffirmed a “hold (c)” rating on the company’s shares. The Royal Bank of Canada raised its price target for Ralliant from $45.00 to $52.00 while maintaining a “sector perform” rating in a report published on November 7, 2025. Citigroup upgraded Ralliant from a “neutral” to a “buy” rating, increasing its price target from $53.00 to $61.00 in a report issued on December 8, 2025. Truist Financial initiated coverage with a “buy” rating and set a target price of $62.00 on December 12, 2025. Oppenheimer also raised its target from $55.00 to $60.00, assigning an “outperform” rating on December 15, 2025. Overall, six equity research analysts currently rate Ralliant as a “buy,” while four have issued “hold” ratings, giving the stock a consensus rating of “Moderate Buy” with an average target price of $58.00, according to data from MarketBeat.com.
About Ralliant
Ralliant, Inc. (NYSE: RAL) is a medical technology company specializing in point-of-care cell therapy solutions within the field of regenerative medicine. The firm develops and markets innovative systems that isolate, concentrate, and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s fat tissue. This process allows for same-day, autologous treatments without extensive laboratory infrastructure. Ralliant’s core product portfolio includes proprietary device platforms and single-use processing kits designed to streamline clinical workflows.
As the company navigates its financial challenges, Ralliant’s commitment to advancing medical technology remains a focal point for investors and analysts alike.
